Arcellx Inc

Arcellx — Investor Relations Event at the 65th ASH Annual Meeting 2023

38 slides from Arcellx's conference presentation, Dec 12, 2023

  1. Slide 1: Investor Relations Event at the 65th ASH Annual Meeting

    Slide 1: Investor Relations Event at the 65th ASH Annual Meeting

    Exhibit 99.1 th Investor Relations Event at the 65 ASH Annual Meeting December 11, 2023

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on informati

  3. Slide 3: Agenda

    Slide 3: Agenda

    Agenda Topic Presenter Time Opening Remarks Rami Elghandour 10 Minutes Chairman and Chief Executive Officer, Arcellx Phase I Study of anito-cel: A CART- Matthew J. Frigault, M.D., M.S. 20 Minutes Therapy Utilizing a Novel Synthetic iMMagine-1 and ACLX-001 Clinical Study Investigator, Binding Domain

  4. Slide 4: Arcellx is a Different Kind of Cell Therapy Company

    Slide 4: Arcellx is a Different Kind of Cell Therapy Company

    Arcellx is a Different Kind of Cell Therapy Company Potential best-in-class therapy partnered with Kite, the global leader in cell therapy. Scalable manufacturing and commercial footprint to support leadership in a $12B+ Multiple Myeloma cell therapy market. Sufficient capital to fund operations int

  5. Slide 5: Arcellx is well positioned for launch and scale

    Slide 5: Arcellx is well positioned for launch and scale

    Arcellx is well positioned for launch and scale D-Domain, A Differentiated Potential Best-in-Class Positioned for Scale and Technology Platform Multiple Myeloma Franchise Success in CAR-T Space ‣ High Expression: Novel synthetic binder ‣ Potential best-in-class profile for ‣ Well capitalized: Strong

  6. Slide 6: Anitocabtagene autoleucel (anito-cel/CART-ddBCMA)

    Slide 6: Anitocabtagene autoleucel (anito-cel/CART-ddBCMA)

    Anitocabtagene autoleucel (anito-cel/CART-ddBCMA) 1 Autologous BCMA-directed CAR T-cell therapy using a novel, D-Domain binder Bi-Valent 2 TCR 4 Camelid VHh (50kDa) (25kDa) 3 scFv (25kDa) D-Domain (8kDa) 41BB 41BB 41BB CD3zCD3z CD3z CD3z CD3z 1 Rotte, et al. Immuno-Oncology Insights 2022; 3(1), 13–2

  7. Slide 7: High CAR+ cell product with lower overall cell dose

    Slide 7: High CAR+ cell product with lower overall cell dose

    High CAR+ cell product with lower overall cell dose Anito-cel has higher transduction efficiency Enabling higher CAR+ within a lower overall cell dose Typical product dose: CAR+ viable T-cell and estimated total cell count per infusion (M cells) 1000 70% 750 500 ~360 250 167 ~15% 0 2 1 Anito-cel Car

  8. Slide 8: Phase 1 Clinical Profile Supports Potential Best-in-Class Candidate

    Slide 8: Phase 1 Clinical Profile Supports Potential Best-in-Class Candidate

    Phase 1 Clinical Profile Supports Potential Best-in-Class Candidate 100% ORR Median PFS No Delayed not reached Neurotoxicities 76% CR/sCR at median follow-up of 26.5 mos. Including no Parkinsonian Symptoms No grade ≥3 CRS and 1 case of Grade 3 CR/sCR rate maintained across In the overall population

  9. Slide 9: Anito-cel Phase 1 in a higher risk patient population

    Slide 9: Anito-cel Phase 1 in a higher risk patient population

    Anito-cel Phase 1 in a higher risk patient population Extramedullary Disease B2M ≥ 5.5 (ISS stage 3) High-Risk Cytogenetics** 50% 30% 40% 25% 40% 30% 20% 30% 15% 20% 28% 36% 35% 20% 39% 29% 34% 10% 18% 24% 16% 10% 14% 10% 20% 5% 13% 0% 0% 0% A An ni it to o- -C ce ell Cartitude-1 Legend-2 KarMMa* A

  10. Slide 10: Multiple Myeloma is a Significant Market Opportunity

    Slide 10: Multiple Myeloma is a Significant Market Opportunity

    Multiple Myeloma is a Significant Market Opportunity Growing opportunity for CAR-T 3rd most solutions as more effective common therapies move to blood cancer earlier line patients Incurable Impacting Multiple disease with 100,000 patients life expectancy annually Myeloma of just over 5 years Limited

  11. Slide 11: A Rich Development Pipeline with Growth in Mind

    Slide 11: A Rich Development Pipeline with Growth in Mind

    A Rich Development Pipeline with Growth in Mind Clinical and Preclinical Pipeline Discovery/ Phase 2 / Indication Platform Phase 1 Current Status / Anticipated Milestone Preclinical Pivotal iMMagine-1 pivotal/ anito-cel Present preliminary data 2H’24 ddCAR Multiple Earlier line Ph 3 Confirmatory RCT

  12. Slide 12: Arcellx Reimagining Cell Therapy

    Slide 12: Arcellx Reimagining Cell Therapy

    Arcellx Reimagining Cell Therapy + Novel Synthetic Positive Interim Phase Partnered with Global Platform Built for Binding Domain 1 Clinical Results Leader in Cell Therapy Potential Success Single-infusion ddCAR 100% ORR; 76% CR/sCR Combining potential ACLX-001 Phase 1 clinical Strong investor base

  13. Slide 13: Agenda

    Slide 13: Agenda

    Agenda Topic Presenter Time Opening Remarks Rami Elghandour 10 Minutes Chairman and Chief Executive Officer, Arcellx Phase I Study of anito-cel: A CART- Matthew J. Frigault, M.D., M.S. 20 Minutes Therapy Utilizing a Novel Synthetic iMMagine-1 and ACLX-001 Clinical Study Investigator, Binding Domain

  14. Slide 14: Abstract: Phase 1 Study of Anito-cel in Relapsed/Refractory Multiple Myeloma

    Slide 14: Abstract: Phase 1 Study of Anito-cel in Relapsed/Refractory Multiple Myeloma

    Abstract: 1023 Phase 1 Study Of Anito-cel For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients 1 2 3 4 5* Matthew Frigault, MD, MS , Jacalyn Rosenblatt, MD , Binod Dhakal, MBBS , Noopur Raje, MD , Daniella Cook, BS , 6

  15. Slide 15: Anito-cel: D-Domain Binder Attributes

    Slide 15: Anito-cel: D-Domain Binder Attributes

    Anitocabtagene autoleucel (anito-cel/CART-ddBCMA) 1 Autologous BCMA-directed CAR T-cell therapy using a novel, D-Domain binder D-Domain Attributes: 1,2 Non-Antibody Derived Synthetic Protein Small D-Domain construct facilitates high transduction Expression efficiency, CAR positivity, and CAR density

  16. Slide 16: Anito-cel Phase 1: Background and Methods

    Slide 16: Anito-cel Phase 1: Background and Methods

    Anito-cel Phase 1: Background and Methods Phase 1 first-in-human trial is in patients with relapsed and/or refractory myeloma • Prior IMiD, PI, and CD38-targeted therapy Anito-cel • Received ≥3 prior lines of therapies or triple refractory 2 Dose Levels evaluated, 6 patients in each dose escalation

  17. Slide 17: Anito-cel Phase 1: Patient Disposition

    Slide 17: Anito-cel Phase 1: Patient Disposition

    Anito-cel Phase 1: Patient Disposition Enrolled and Leukapheresed n=40 Successful Manufacture of Anito-cel n=40 Discontinued: Infection, n=1 Lymphodepletion n=39 Discontinued: Hypoxia/Heart Failure, n=1 Total Dosed n=38 6 6 DL1, 100x10 CAR+ cells DL2, 300x10 CAR+ cells n=32 n=6 Safety and Efficacy e

  18. Slide 18: Anito-cel Phase 1: A higher risk patient population

    Slide 18: Anito-cel Phase 1: A higher risk patient population

    Anito-cel Phase 1: A higher risk patient population 4 6 7 KarMMa Legend-2 Cartitude-1 Anito-cel ph1 ‣ Greater percentage of patients N=128 N=74 N=97 N=38 with poor prognostic features: Anito-cel Phase 1 has higher rates BMPC > 60%, # (%) NA NA 21 (22%) 9 (24%) of patients with high tumor burden, ISS

  19. Slide 19: Greater proportion of patients with ISS Stage III

    Slide 19: Greater proportion of patients with ISS Stage III

    Greater proportion of patients with ISS Stage III 4 6 7 KarMMa Legend-2 Cartitude-1 Anito-cel ph1 ‣ Greater percentage of patients N=128 N=74 N=97 N=38 with poor prognostic features: Anito-cel Phase 1 has higher rates BMPC > 60%, # (%) NA NA 21 (22%) 9 (24%) of patients with high tumor burden, ISS s

  20. Slide 20: Greater proportion of patients with EMD

    Slide 20: Greater proportion of patients with EMD

    Greater proportion of patients with EMD 4 6 7 KarMMa Legend-2 Cartitude-1 Anito-cel ph1 ‣ Greater percentage of patients N=128 N=74 N=97 N=38 with poor prognostic features: Anito-cel Phase 1 has higher rates BMPC > 60%, # (%) NA NA 21 (22%) 9 (24%) of patients with high tumor burden, ISS stage III,

  21. Slide 21: Greater proportion of patients with High-Risk Cytogenetics

    Slide 21: Greater proportion of patients with High-Risk Cytogenetics

    Greater proportion of patients with High-Risk Cytogenetics 4 6 7 KarMMa Legend-2 Cartitude-1 Anito-cel ph1 ‣ Greater percentage of patients N=128 N=74 N=97 N=38 with poor prognostic features: Anito-cel Phase 1 has higher rates BMPC > 60%, # (%) NA NA 21 (22%) 9 (24%) of patients with high tumor burd

  22. Slide 22: Greater proportion of patients age ≥65

    Slide 22: Greater proportion of patients age ≥65

    Greater proportion of patients > 65 4 6 7 KarMMa Legend-2 Cartitude-1 Anito-cel ph1 ‣ Greater percentage of patients N=128 N=74 N=97 N=38 with poor prognostic features: Anito-cel Phase 1 has higher rates BMPC > 60%, # (%) NA NA 21 (22%) 9 (24%) of patients with high tumor burden, ISS stage III, EMD,

  23. Slide 23: Greater proportion of patients that are Penta Refractory

    Slide 23: Greater proportion of patients that are Penta Refractory

    Greater proportion of patients that are Penta Refractory 4 6 7 KarMMa Legend-2 Cartitude-1 Anito-cel ph1 ‣ Greater percentage of patients N=128 N=74 N=97 N=38 with poor prognostic features: Anito-cel Phase 1 has higher rates BMPC > 60%, # (%) NA NA 21 (22%) 9 (24%) of patients with high tumor burden

  24. Slide 24: High CR/sCR rate of 76%, maintained across high-risk groups

    Slide 24: High CR/sCR rate of 76%, maintained across high-risk groups

    High CR/sCR rate of 76%, maintained across high-risk groups 100% 8% 8% 8% 9% 10% 90% 8% 8% 5% 9% 16% 80% 70% 60% PR VGPR 50% 85% sCR/CR 85% 83% 82% 40% 76% 30% 20% 10% 0% All Subjects High Risk* EMD High Risk Cytogenetics Age ≥65 (N=38) (N=24) (N=13) (N=11) (N=20) Note: Data cut-off October 15, 2023

  25. Slide 25: Anito-cel has 100% ORR and 76% CR/sCR in Phase 1

    Slide 25: Anito-cel has 100% ORR and 76% CR/sCR in Phase 1

    Anito-cel has 100% ORR and 76% CR/sCR in Phase 1 100% 99.6% 97.9% 100% 87.8% 15% 90% 24% 26% 15% 80% 73.4% 70% ORR 60% VPGR+PR 40% 50% CR/sCR 82% 40% 76% 74% 73% 30% 20% 33% 10% 0% Anito-cel Cartitude-1 MAIC Legend-2 Cartitude-1 KarMMa 26.5 mo. follow-up 27.7 mo. follow-up 47.8 mo. follow-up 27.7 mo

  26. Slide 26: mPFS not reached at 26.5 mo median follow-up (all patients)

    Slide 26: mPFS not reached at 26.5 mo median follow-up (all patients)

    mPFS not reached at 26.5 mo median follow-up (all patients) Time PFS Estimate 95% Confidence (months) (%) Interval (%) 6 92.1 77.5, 97.4 12 75.9 58.7, 86.6 All Patients (n = 38) 18 63.7 45.7, 77.2 24 56.0 37.3, 71.1 § Median PFS not reached for all patients (n=38) § Median PFS not reached for CR/sCR

  27. Slide 27: mPFS not reached at 26.5 mo median follow-up (all patients)

    Slide 27: mPFS not reached at 26.5 mo median follow-up (all patients)

    mPFS not reached at 26.5 mo median follow-up (all patients) Anito-Cel Phase 1 median follow-up 26.5 mos Cartitude-1 8 median follow-up 27.7 mos Cartitude-1 MAIC 8 median follow-up 27.7 mos KarMMA 8 median follow-up 15.4 mos Note: MAIC is matching-adjusted indirect comparison, a J&J study comparing C

  28. Slide 28: Anito-cel mPFS not reached in EMD and Non-EMD patients

    Slide 28: Anito-cel mPFS not reached in EMD and Non-EMD patients

    Anito-cel mPFS not reached in EMD and Non-EMD patients PFS Time 95% Confidence Estimate (months) Interval (%) (%) 6 92.3 56.6, 98.9 12 67.1 34.2, 86.2 With EMD (n = 13) 18 67.1 34.2, 86.2 24 57.5 25.7, 79.9 § Median PFS not reached for patients with EMD (n=13) § Median PFS not reached for Non-EMD pa

  29. Slide 29: Durability tracking to >24 mo. mPFS in high-risk populations

    Slide 29: Durability tracking to >24 mo. mPFS in high-risk populations

    Durability tracking to >24 mo. mPFS in high-risk populations Kaplan-Meier High Risk Extramedullary High Risk Overall ≥ 65 years PFS Estimates Features* disease Cytogenetics Patients n 38 24 13 11 20 (%) (100%) (63.2%) (34.2%) (28.9%) (52.6%) 6-month PFS % 92.1% 91.7% 92.3% 81.8% 95.0% (95% CI) (77.5

  30. Slide 30: Durability highlights potential best-in-class profile

    Slide 30: Durability highlights potential best-in-class profile

    Durability highlights potential best-in-class profile mPFS 0 6 12 18 24 30 36 42 Anito-cel Not Reached 27-month estimated PFS: 51% 26.5-mo. (at 26.5 mo. median follow-up) median follow-up Cartitude-1 Not Reached 27.7-mo. 27-month estimated PFS: 55% 7 (at 27.7 mo. median follow-up) median follow-up C

  31. Slide 31: Durability maintained in EMD patients, a poor prognostic factor

    Slide 31: Durability maintained in EMD patients, a poor prognostic factor

    Durability maintained in EMD patients, a poor prognostic factor mPFS 0 6 12 18 24 30 36 42 Anito-cel Not Reached (100% EMD) (at ~33 mo. median follow-up) RWE CAR-T 12.4 months 9 (100% EMD) Legend-2 (~68% EMD, ~32% bone- 8.9 months 6 based) Cartitude-1 (~68% EMD, ~32% bone- 13.8 months 7 based) KarMM

  32. Slide 32: The typical patient in the Anito-Cel Phase 1 had a high-risk feature

    Slide 32: The typical patient in the Anito-Cel Phase 1 had a high-risk feature

    The typical patient in the Anito-Cel Phase 1 had a high-risk feature, where approved CAR-Ts have had poor outcomes mPFS 0 6 12 18 24 30 Anito-cel Ph 1 High-Risk Features* 24-mo est. PFS: 59% (n=24/38, 63%) Cartitude-1 Plasmacytoma 13.8 months 7 (~68% EMD; ~32% bone-based lesions) 63% Cartitude-1 ISS

  33. Slide 33: At 2-yrs follow-up, Anito-cel has favorable safety profile

    Slide 33: At 2-yrs follow-up, Anito-cel has favorable safety profile

    At 2-yrs follow-up, Anito-cel has favorable safety profile • No delayed neurotoxicities, no Parkinsonian-like syndromes • No cranial nerve palsies, no Guillain-Barré syndrome, in the entire population through follow-up • One Grade 5 AE post study treatment (unrelated cardiac arrest due to non-study

  34. Slide 34: iMMagine-1 Phase 2 Pivotal Trial Currently Enrolling

    Slide 34: iMMagine-1 Phase 2 Pivotal Trial Currently Enrolling

    iMMagine-1 Phase 2 Pivotal Trial Currently Enrolling A multicenter, open-label study of CART-ddBCMA in patients with r/r MM Primary Endpoint Overall Response Rate (ORR) per IMWG criteria by Independent Review Committee (IRC) ‣ The primary analysis is planned when all subjects have a minimum of 13 mo

  35. Slide 35: Conclusions

    Slide 35: Conclusions

    Conclusions § Anito-cel utilizes a novel, synthetic, compact and stable D-Domain binder o D-Domain facilitates high CAR surface expression, low risk of tonic signaling o Recommended Phase 2 Dose selected as 115±10 million CAR+ T cells § CR/sCR rate 76%; 100% ORR per IMWG o CR/sCR rate >80% in all ev

  36. Slide 36: Arcellx Panel Discussion

    Slide 36: Arcellx Panel Discussion

    Arcellx Panel Discussion Christopher Heery, Matthew J. Frigault, Krina K. Patel, M.D. M.D., M.S. M.D., M.Sc. Chief Medical Officer, Arcellx iMMagine-1 and ACLX-001 Clinical iMMagine-1 Clinical Study Study Investigator, Clinical Investigator, Associate Director of the Cellular Therapy Professor, Depa

  37. Slide 37: Q&A

    Slide 37: Q&A

    Q&A 37 A Arrc c ee llx ll x | 2023 ASH IR Event

  38. Slide 38: References

    Slide 38: References

    References 1. Zudair et al., “Translational learnings from Cilta-cel, a BCMA-targeted CAR-T Cell Therapy”, CAR-TCR (2022) 2. Foster et al. “Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project”, Molecular Therapy Oncolytics, Vol 27: Dec 2022. https

Source: SEC EDGAR · 8-K filed Dec 12, 2023

More decks from Arcellx Inc